In the past week, BCYC stock has gone up by 23.48%, with a monthly decline of -3.85% and a quarterly plunge of -35.62%. The volatility ratio for the week is 9.18%, and the volatility levels for the last 30 days are 8.74% for Bicycle Therapeutics Plc ADR The simple moving average for the past 20 days is 13.62% for BCYC’s stock, with a -51.56% simple moving average for the past 200 days.
Is It Worth Investing in Bicycle Therapeutics Plc ADR (NASDAQ: BCYC) Right Now?
BCYC has 36-month beta value of 1.59. Analysts have mixed views on the stock, with 4 analysts rating it as a “buy,” 5 as “overweight,” 3 as “hold,” and 0 as “sell.”
The public float for BCYC is 61.30M, and currently, short sellers hold a 7.02% ratio of that float. The average trading volume of BCYC on April 23, 2025 was 338.33K shares.
BCYC) stock’s latest price update
The stock of Bicycle Therapeutics Plc ADR (NASDAQ: BCYC) has increased by 16.24 when compared to last closing price of 7.51.Despite this, the company has seen a gain of 23.48% in its stock price over the last five trading days. seekingalpha.com reported 2025-04-22 that Bicycle Therapeutics focuses on novel conjugated targeted therapies for cancer, with promising early results but no clear evidence of superior efficacy yet. Their lead compound, zelenectide pevedotin, shows potential in urothelial carcinoma with a 45% response rate, but more robust studies are needed. Financially, BCYC is well-capitalized with $879.5 million in cash, providing a runway into 2027 despite high operating expenses.
Analysts’ Opinion of BCYC
Many brokerage firms have already submitted their reports for BCYC stocks, with Stephens repeating the rating for BCYC by listing it as a “Equal-Weight.” The predicted price for BCYC in the upcoming period, according to Stephens is $25 based on the research report published on November 08, 2024 of the previous year 2024.
RBC Capital Mkts, on the other hand, stated in their research note that they expect to see BCYC reach a price target of $35. The rating they have provided for BCYC stocks is “Outperform” according to the report published on September 06th, 2024.
B. Riley Securities gave a rating of “Neutral” to BCYC, setting the target price at $28 in the report published on August 07th of the previous year.
BCYC Trading at -8.44% from the 50-Day Moving Average
After a stumble in the market that brought BCYC to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -69.55% of loss for the given period.
Volatility was left at 8.74%, however, over the last 30 days, the volatility rate increased by 9.18%, as shares sank -5.11% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -28.33% lower at present.
During the last 5 trading sessions, BCYC rose by +23.48%, which changed the moving average for the period of 200-days by -55.41% in comparison to the 20-day moving average, which settled at $7.68. In addition, Bicycle Therapeutics Plc ADR saw -37.64% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at BCYC starting from Young Alethia, who sale 215 shares at the price of $8.02 back on Apr 02 ’25. After this action, Young Alethia now owns 45,390 shares of Bicycle Therapeutics Plc ADR, valued at $1,724 using the latest closing price.
Skynner Michael, the CHIEF TECHNOLOGY OFFICER of Bicycle Therapeutics Plc ADR, sale 1,038 shares at $7.48 during a trade that took place back on Apr 03 ’25, which means that Skynner Michael is holding 121,870 shares at $7,764 based on the most recent closing price.
Stock Fundamentals for BCYC
Current profitability levels for the company are sitting at:
- -6.61 for the present operating margin
- 0.84 for the gross margin
The net margin for Bicycle Therapeutics Plc ADR stands at -4.79. The total capital return value is set at -0.26. Equity return is now at value -29.06, with -21.79 for asset returns.
Based on Bicycle Therapeutics Plc ADR (BCYC), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -17.35. The debt to equity ratio resting at 0.01. The interest coverage ratio of the stock is -134.73.
Currently, EBITDA for the company is -164.89 million with net debt to EBITDA at 4.84. When we switch over and look at the enterprise to sales, we see a ratio of -7.57. The receivables turnover for the company is 0.99for trailing twelve months and the total asset turnover is 0.04. The liquidity ratio also appears to be rather interesting for investors as it stands at 13.81.
Conclusion
To put it simply, Bicycle Therapeutics Plc ADR (BCYC) has had a bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
